• Aliases: Anti-CD38 monoclonal antibody; JNJ-54767414
    • A fully human mAb directed against the cell surface glycoprotein CD-38 that is found on the surfaces of hematopoietic cells, including MM cells.
    • FDA approved for the treatment of patients with MM previously treated with at least three prior regimens, including a proteasome inhibitor and an immunomodulatory agent and are refractory to it.
    • Recommended dose: 16 mg/kg (diluted) IV once every week for 8 weeks, once every 2 weeks for 16 weeks, then once every month thereafter. Need premedications with IV corticosteroids, oral acetaminophen, and IV or an equivalent H1 antagonist
    Other topics in Targeted and Immunotherapy Agents